Report cover image

IgA Nephropathy Treatment Market - 2025-2033

Publisher DataM Intelligence 4Market Research LLP
Published Mar 20, 2026
Length 217 Pages
SKU # DTAM21122888

Description

IgA Nephropathy Treatment Market Overview:
The IgA Nephropathy Treatment Market was valued at US$ 525.43 million in 2025 and is anticipated to reach US$ 2674.01 million by 2033, at a CAGR of 0.2241 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the IgA Nephropathy Treatment Market.

This report delivers a comprehensive overview of the IgA Nephropathy Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding IgA Nephropathy Treatment Market. The IgA Nephropathy Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

IgA Nephropathy Treatment Market Scope:
Key Players
• Key Market Players
• Travere Therapeutics, Inc.
• Calliditas Therapeutics AB
• STADA Arzneimittel
• Everest Medicines
• Viatris Inc.
• Novartis AG
• Emerging Market Players

Major Highlights
This report delivers a comprehensive overview of the IgA Nephropathy Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding IgA Nephropathy Treatment Market. The IgA Nephropathy Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

217 Pages
1. Market Introduction and Scope
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. Executive Insights and Key Takeaways
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Disease Type
2.4. Snippet by Drug
2.5. Snippet by Gender
2.6. Snippet by Region
3. Dynamics
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Innovation in Product Development and Novel Product Approvals
3.1.1.2. Rising Prevalence of IgA Nephropathy
3.1.1.3. Advanced Diagnostics Tools
3.1.2. Restraints
3.1.2.1. High Cost of Approved Therapies
3.1.2.2. Patient compliance issues
3.1.2.3. Limited Awareness in Emerging Markets
3.1.3. Opportunities
3.1.3.1. Rising Access to Advanced Drugs in Emerging Countries
3.1.3.2. Patient-Centric and At-Home Solutions
3.1.3.3. Expansion in Asia-Pacific and Emerging Markets
3.1.4. Impact Analysis
4. Strategic Insights and Industry Outlook
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. Global IgA Nephropathy Treatment Market, By Disease Type
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
5.1.2. Market Attractiveness Index, By Disease Type
5.2. Primary IgA Nephropathy*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Secondary IgA Nephropathy
6. Global IgA Nephropathy Treatment Market, By Drug
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
6.1.2. Market Attractiveness Index, By Drug
6.2. ACE Inhibitors*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Angiotensin Receptor Blockers
6.4. Dual Endothelin Angiotensin Receptor Antagonists (DEARAs)
6.5. SGLT2 Inhibitors
6.6. Corticosteroids
6.7. Endothelin Receptor Antagonists (ETA)
6.8. Others
7. Global IgA Nephropathy Treatment Market, By Gender
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
7.1.2. Market Attractiveness Index, By Gender
7.2. Male*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Female
8. Global IgA Nephropathy Treatment Market, By Region
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
9. Competitive Landscape and Market Positioning
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. Company Profiles
10.1. Key Market Players
10.2. Travere Therapeutics, Inc.*
10.2.1. Company Overview
10.2.1.1. Product Portfolio
10.2.1.2. Product Description
10.2.1.3. Product Key Performance Indicators (KPIs)
10.2.1.4. Historic and Forecasted Product Sales
10.2.1.5. Product Sales Volume
10.2.2. Financial Overview
10.2.2.1. Company Revenue’s
10.2.2.2. Geographical Revenue Shares
10.2.2.3. Revenue Forecasts
10.2.3. Key Developments
10.2.3.1. Mergers & Acquisitions
10.2.3.2. Key Product Development Activities
10.2.3.3. Regulatory Approvals, etc.
10.2.4. SWOT Analysis
10.3. Calliditas Therapeutics AB
10.4. STADA Arzneimittel
10.5. Everest Medicines
10.6. Viatris Inc.
10.7. Novartis AG
10.8. Emerging Market Players
10.8.1. Vertex Pharmaceuticals Incorporated
10.8.2. RemeGen
10.8.3. Wuxi BioCity
10.8.4. F. Hoffmann-La Roche Ltd/Ionis Pharmaceuticals
10.8.5. Vera Therapeutics.
10.8.6. Otsuka Pharmaceutical Co., Ltd.
10.8.7. Alexion Pharmaceuticals, Inc.
10.8.8. Takeda Pharmaceutical Company Limited.
10.8.9. Wuhan Createrna Science and Technology Co.,Ltd. (* Similar data will be provided for each market player.) LIST NOT EXHAUSTIVE
11. Appendix
11.1. About Us and Services
11.2. Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us